The effects of the angiotensin-converting enzyme inhibitor ramipril on thirteen endocrinological tests were evaluated. These tests comprised serum follitropin, lutropin, prolactin, thyrotropin, free thyroxine, total thyroxine, free triiodothyronine, parathyrin, cortisol, testosterone, sex hormone binding globulin, androstenedione and dehydroepiandrosterone sulphate.
Introduction
ramiprilat, in the liver (8 ' 'atecholamines, vasopressin (9) and inlosporines are known to interfere with current methods sulin < 12 > have been studied ^ P resent studv was car ' for measuring creatinine (6, 7) . ried out to examine whether rami P ril has other endocri -nological effects. The interfering drug effects should be known and they should also be recognized by clinicians in order to interpret laboratory test results correctly. Since new drugs Materials and Methods and new laboratory methods are introduced frequently, Subjects laboratory staff should be alert and eager to actively The study population consisted of 11 patients with essential hypersearch for drug effects on laboratory tests. For this purtension, 9 men and 2 women, mean age 41. Ramipril is a long-acting angiotensin-converting enzyme once a for me study period of four weeks Subjects were tested inhibitor, which is converted to its active metabolite, for serum follitropin, lutropin, prolactin, thyrotropin, free thyrox-ine, total thyroxine, free triiodothyronine, parathyrin, cortisol, testosterone, sex hormone binding globulin, androstenedione and dehydroepiandrosterone sulphate before medication and at the end of the study period. Blood samples were taken between 7 a.m. and 9a.m. after fasting from 10p.m. the previous evening. Methods, manufacturers and coefficients of inter-assay variation (CV%) of the assays are displayed in table 1. The study protocol was approved by the Ethics Committee of the Turku University Central Hospital and the study followed the recommendations for biomedical research involving human subjects according to the current version of the Declaration of Helsinki.
Statistics
The 95% confidence interval for the within-subject difference in a paired case was used as a measure of statistical significance. Student's t-test (paired, two-sided) was used to find out the exact pvalue (13) .
Results
The effects of ramipril on the hormonal status of study patients are shown in 
Discussion and Conclusion
The effects of angiotensin-converting enzyme inhibitors on endocrinological tests are not well known (2) . Generally, angiotensin-converting enzyme inhibitors are shown to decrease serum aldosterone concentration and increase serum renin concentration (2), which also applies to ramipril (9, 11) . Serum insulin has been found to decrease, increase or remain unaffected depending on the angiotensin-converting enzyme inhibitor (2) . According to earlier studies, angiotensin-converting enzyme inhibitors do not affect the concentration of serum cortisol, catecholamines and antidiuretic hormone (2) . Similarly, during ramipril treatment, the level of insulin secretion (12), cortisol, catecholamines and vasopressin (9) have been reported to remain unaffected.
In the present study, the effects of ramipril on 13 endocrinological tests were examined. No major endocrinological effects were found. Ramipril did not affect serum cortisol concentration, which is in line with the findings of Crazier and co-workers (9) . Neither did ramipril have statistically significant effects on serum follitropin, lutropin, prolactin, thyrotropin, total thyroxine, free triiodothyronine, parathyrin, testosterone, sex hormone binding globulin, androstenedione or dehydroepiandrosterone sulphate concentrations.
However, serum free thyroxine decreased from the mean concentration of 17.1 pmol/1 to the mean concentration of 16.0 pmol/1 during ramipril treatment when measured with Amerlex-MAB*, which was the standard free thyroxine assay in our laboratory during the study. As the specimens were reanalyzed with the new Auto-DELFIA™ assay, no effect of ramipril was detected. Whenever an unexpected drug effect on a laboratory test is found, it is essential to assess the nature of the effect as analytical or biological. A biological effect causes a real increase or decrease of a biochemical component whereas an analytical effect is associated only with the method used in measuring. The minimal evidence needed for this classification requires at least two assays based on different methodological principles. To be certain about the nature of the effect, the specimens were reanalyzed using the reference method for free thyroxine, dialysis+RIA (14) . The results of the dialysis+RIA were parallel with the AutoDELFIA™, i. e., no effect of ramipril on free thyroxine concentration was detected. Accordingly, the decreasing effect of ramipril on free thyroxine was associated with the Amerlex-MAB* but neither with the AutoDELFIA™ nor with dialysis+RIA. The decreasing effect of ramipril on free thyroxine was therefore concluded to be analytical.
Free thyroxine immunoassays have been strongly criticized because of the misleading diagnostic results they often yield due to abnormal serum concentrations of albumin or other proteins, antibodies or inhibitors of hormone binding (15, 16) . Recently, Van Blerk and coworkers (17) compared four radioisotope immunoassays of free thyroxine and they evaluated the performance of Amerlex-MAB* free thyroxine as excellent. Endogenous albumin, however, was found to interfere with the method and have weak positive correlation with free thyroxine results. According to our measurements, ramipril did not affect the concentration of serum albumin (data not shown) and therefore albumin could not be the component interfering with the Amerlex-MAB* free thyroxine in this study. The mechanism of the effect is still unknown. All the same, the AutoDELFIA™ free thyroxine assay based on the back-titration principle was less sensitive to the interfering components in the specimens.
In Turku University Central Hospital we use a computerized system for managing patient medication data, laboratory data and drug-laboratory interference data (18) (19) (20) . Utilizing this system, we found that 20% of the patients tested for free thyroxine in our hospital were treated with an angiotensin-converting enzyme inhibitor. In the light of this finding and the fact that the Amerlex-MAB* assay is widely and commonly used, the effect of ramipril or possibly all angiotensin-converting enzyme inhibitors on free thyroxine is probably quite a common problem in laboratories. Even though the decrease in free thyroxine was slight and none of the patients in this study was misclassified as hypothyroid, attention should be paid to this problem, because misclassification of hyperthyroid patients as normal or normal patients as hypothyroid may occur in borderline cases.
